Therapeutic effect of FDP combined with levocarnitine on patients with viral myocarditis and its effect on serum AST,LDH,cTnI
10.3969/j.issn.1008-0074.2025.03.15
- VernacularTitle:FDP联合左卡尼汀对病毒性心肌炎患者的疗效及对血清AST、LDH、cTnI的影响
- Author:
Jian-jian LIU
1
;
Peng-rong DU
;
Qin ZHANG
Author Information
1. 榆林市星元医院心血管内二科,陕西榆林 719000
- Publication Type:Journal Article
- Keywords:
Viral myocarditis;
Levocarnitine;
1,6-Fructose Diphosphate
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2025;34(3):362-367
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of levocarnitine combined with fructose 1,6-diphosphate(FDP)on patients with viral myocarditis(VMC)and its effect on serum levels of aspartate aminotransferase(AST),lactate dehydrogenase(LDH)and cardiac troponin I(cTnI).Methods:This randomized controlled study enrolled 126 patients with VMC admitted to Xingyuan Hospital of Yulin between May 2020 and August 2021.Pa-tients were divided into control group(n=63)and intervention group(n=63).Patients in the control group re-ceived routine treatment comparing to those in the intervention group receiving additional FDP combined with levoc-arnitine,both groups were treated for 4 weeks.Left ventricular ejection fraction(LVEF),levels of AST,LDH,cTnI,creatine kinase(CK),creatine kinase isoenzyme MB(CK-MB)and therapeutic effective rate were com-pared between the two groups.Pearson correlation analysis was used to analyze the association of AST,LDH,cTnI levels with LVEF.Results:Compared with patients in control group after 4-week treatment,those in the inter-vention group had significant higher LVEF[(73.17±6.39)％vs.(63.30±6.04)％]and therapeutic effective rate(96.67％vs.80.00％)(P＜0.001 all),and significant lower levels of AST[(32.35±7.34)U/L vs.(48.22±8.40)U/L],LDH[(154.50±28.10)U/Lvs.(183.77±29.60)U/L],cTnI[(77.47±12.04)ng/ml vs.(96.12±15.33)ng/ml],CK[(181.47±8.93)U/L vs.(192.33±8.85)U/L],CK-MB[(24.25±2.19)U/L vs.(28.17±2.01)U/L](P＜0.001 all).Pearson correlation analysis indicated that AST,LDH and cTnI levels were significant negatively correlated with LVEF(r=-0.404,-0.231,-0.339,P＜0.05 or＜0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P=0.543).Conclusion:FDP combined with levocarnitine could significantly improve cardiac function,reduce the levels of AST,LDH and cTnI,and effectively improve therapeutic effective rate with good safety in patients with viral myocarditis.
